Skip to main content

伊利诺伊州威尔梅特、威斯康星州贝洛伊特和德克萨斯州安格尔顿

Written by Customer Service on . Posted in Public Companies.

UTRECHT (Pays-Bas), et CAMBRIDGE, Massachusetts (États-Unis), 08 août 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS), société d’oncologie de stade clinique qui développe des anticorps innovants et multispécifiques pleine longueur (Biclonics® et Triclonics™), a annoncé aujourd’hui que Bill Lundberg, M.D., président-directeur général, présenterait une vue d’ensemble de la société lors de la Wedbush PacGrow Healthcare Conference 2020 le mercredi 12 août 2020 à 10 h 20 HNE.
Une diffusion en direct de la présentation sera disponible sur la page consacrée aux investisseurs du site Web de la Société, http://www.merus.nl. Une présentation archivée sera disponible sur le site Web de Merus pendant une durée limitée.À propos de Merus
Merus est une entreprise d’oncologie de stade clinique qui développe des traitements innovants à base d’anticorps bispécifiques et trispécifiques humains pleine longueur, appelés Multiclonics®. Les Multiclonics® sont fabriqués selon les procédés standard de l’industrie. Des études précliniques et cliniques ont montré qu’ils possèdent plusieurs caractéristiques identiques à celles des anticorps monoclonaux humains conventionnels, notamment une longue demi-vie et une faible immunogénicité. Pour tout complément d’information, veuillez consulter les sites Web de Merus : www.merus.nl et https://twitter.com/MerusNV.Relations avec les investisseurs et les médias chez Merus :
Jillian Connell
Merus N.V.
Relations avec les investisseurs et communications d’entreprise
+1 617-955-4716

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.